Figure 2.

A. Altered genes in patients used for treatment selection with a genotype-matched therapy. B. Alteration actionability as classified by PODS for alterations subsequently acted on by physicians. C. Type of therapy received for patients with alterations receiving genotype-matched therapy. D. Alterations (gene level) which physicians deemed to be not actionable, but for which a call by the genomic annotators would have been classified as either “actionable” or “potentially actionable.”